Use of the 6-Min Walk Distance to Identify Variations in Treatment Benefits From Implantable Cardioverter-Defibrillator and Amiodarone

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:63

Article

Fishbein, Daniel P.¹  Hellkamp, Anne S.²  Mark, Daniel B.³  Walsh, Mary Norine⁴  Poole, Jeanne E.¹  Anderson, Jill⁵  Johnson, George⁵  Lee, Kerry L.²  Bardy, Gust H.^1,5 

[1] Univ Washington, Dept Med, Div Cardiol, Seattle, WA 98195 USA

[2] Duke Univ, Dept Stat, Duke Clin Res Inst, Durham, NC USA

[3] Duke Univ, Dept Med, Div Cardiol, Durham, NC USA

[4] St Vincent Heart Ctr Indiana, Indianapolis, IN USA

[5] Seattle Inst Cardiac Res, Seattle, WA USA

关键词: 6-min walk;    amiodarone;    congestive heart failure;    implantable cardioverter-defibrillator;    sudden cardiac death;   

DOI  :  10.1016/j.jacc.2014.02.602

来源: Elsevier

【 摘 要 】

Objectives The purpose of this study was to determine if 6-min walk test data assists in treatment decisions for patients with heart failure. Background In the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial), a pre-specified subgroup analysis showed that patients with New York Heart Association functional class III symptoms did not benefit from implantable cardioverter-defibrillator (ICD) therapy and appeared to be harmed by amiodarone, whereas New York Heart Association functional class II patients obtained significant survival benefit from ICD. We postulated that a more objective measure of functional capacity, such as 6-min walk (6MW) distance, might provide a better tool for selecting these preventive therapies. Methods A 6MW test was performed before randomization in 2,397 patients. Median follow-up was 45.5 months. All-cause mortality was the primary endpoint, with cause-specific mortality (heart failure, arrhythmic) examined in secondary analyses. Results The hazard ratios (HRs) for ICD therapy compared to placebo were estimated within tertiles of baseline 6MW distance: HR: 0.42 (95% confidence interval [ CI]: 0.26 to 0.66) for 6MW distance > 386 m (top tertile); HR: 0.57 (95% CI: 0.39 to 0.83) for 6MW distance 288 to 386 m (middle tertile); and HR: 1.02 (95% CI: 0.75 to 1.39) for 6MW distance < 288 m (bottom tertile). The corresponding HRs for amiodarone compared to placebo were 0.68 (95% CI: 0.46 to 1.02) for the top, 0.86 (95% CI: 0.61 to 1.21) for the middle, and 1.56 (95% CI: 1.17 to 2.09) for the bottom tertile. The 6MW distance was inversely related to heart failure-related mortality but not to arrhythmic mortality. ICD therapy reduced arrhythmic mortality in the top 2 tertiles of 6MW, but had no effect on heart failure mortality. Conclusions A baseline 6MW distance < 288 m identified a subgroup of SCD-HeFT patients who were harmed by amiodarone therapy and did not benefit from ICD. (C) 2014 by the American College of Cardiology Foundation

【 授权许可】

Free